Beyond valproate: considerations for the general paediatrician

Abstract

Over the last year, new Medicines and Healthcare products Regulatory Agency (MHRA) regulations for the use of sodium valproate in females and males have had a significant impact on clinical practice. This article uses a case as an anchor, to understand what these regulations mean in clinical practice. We highlight that knowledge about the regulations, together with a holistic view of the patient is important to choose the most effective and tolerated medication. Professional guidelines which offer valuable support with the practicalities are highlighted in the further reading sections.